Computational Identification of Chemical Compounds with Potential Activity against Leishmania amazonensis using Nonlinear Machine Learning Techniques.

Journal: Current topics in medicinal chemistry
Published Date:

Abstract

Leishmaniasis is a poverty-related disease endemic in 98 countries worldwide, with morbidity and mortality increasing daily. All currently used first-line and second-line drugs for the treatment of leishmaniasis exhibit several drawbacks including toxicity, high costs and route of administration. Consequently, the development of new treatments for leishmaniasis is a priority in the field of neglected tropical diseases. The aim of this work is to develop computational models those allow the identification of new chemical compounds with potential anti-leishmanial activity. A data set of 116 organic chemicals, assayed against promastigotes of Leishmania amazonensis, is used to develop the theoretical models. The cutoff value to consider a compound as active one was IC50≤1.5μM. For this study, we employed Dragon software to calculate the molecular descriptors and WEKA to obtain machine learning (ML) models. All ML models showed accuracy values between 82% and 91%, for the training set. The models developed with k-nearest neighbors and classification trees showed sensitivity values of 97% and 100%, respectively; while the models developed with artificial neural networks and support vector machine showed specificity values of 94% and 92%, respectively. In order to validate our models, an external test-set was evaluated with good behavior for all models. A virtual screening was performed and 156 compounds were identified as potential anti-leishmanial by all the ML models. This investigation highlights the merits of ML-based techniques as an alternative to other more traditional methods to find new chemical compounds with anti-leishmanial activity.

Authors

  • Juan Alberto Castillo-Garit
    Unidad de Toxicologia Experimental, Universidad de Ciencias Medicas de Villa Clara, Santa Clara, 50200, Cuba.
  • Naivi Flores-Balmaseda
    CAMD-BIR Unit, Chemistry-Pharmacy Faculty, Universidad Central de Las Villas, Santa Clara, 54830, Cuba.
  • Orlando Álvarez
    CAMD-BIR Unit, Chemistry-Pharmacy Faculty, Universidad Central de Las Villas, Santa Clara, 54830, Cuba.
  • Hai Pham-The
    Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hoan Kiem, Hanoi, Vietnam.
  • Virginia Pérez-Doñate
    Departamento de Microbiologia. Hospital Universitario de la Ribera, Valencia, Spain.
  • Francisco Torrens
    Institut Universitari de Ciència Molecular, Universitat de València, Edifici d' Instituts de Paterna, P,O, Box 22085, València, Spain.
  • Facundo Pérez-Giménez
    Unidad de Investigacion de Diseno de Farmacos y Conectividad Molecular, Departamento de Quimica Física, Facultad de Farmacia, Universitat de Valencia, Valencia, Spain.